Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "BRII-835 + BRII-179 Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
"BRII-835 + BRII-179 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about BRII-835 + BRII-179 for chronic hepatitis B in the seven major markets and China. A detailed picture of the BRII-835 + BRII-179 for chronic hepatitis B in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China for the study period 2019-2032 is provided in this report along with a detailed description of the BRII-835 + BRII-179 for chronic hepatitis B.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BRII-835 + BRII-179 market forecast analysis for chronic hepatitis B in the 7MM and China, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.
Drug Summary
BRII-836 (VIR-2218) is an investigational subcutaneously administered HBV-targeting siRNA that can stimulate an effective immune response and have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index.
Also, BRII-179 (VBI-2601) is a novel recombinant, protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens and is designed to induce enhanced B-cell and T-cell immunity. Brii Bio licensed BRII-179 (VBI-2601) from VBI Vaccines in December 2018, providing Brii Bio with commercial rights to BRII-179 (VBI-2601) in the licensed territories of Mainland China, China Hong Kong, Macau, and Taiwan.
Both agents have demonstrated proof of mechanism in HBV patients; a combination might be a potential functional cure. It encompasses dual mechanisms of action, removing immunosuppressive viral antigens by siRNA gene silencing followed by stimulating and restoring the host HBV-specific immunity with an immunotherapeutic vaccine.
BRII-835 + BRII-179 Analytical Perspective
In-depth BRII-835 + BRII-179 Market Assessment
This report provides a detailed market assessment of BRII-835 + BRII-179 for chronic hepatitis B in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China. This segment of the report provides forecasted sales data from 2027 to 2032.
BRII-835 + BRII-179 Clinical Assessment
The report provides the clinical trials information of BRII-835 + BRII-179 for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions Answered
- What is the product type, route of administration and mechanism of action of BRII-835 + BRII-179?
- What is the clinical trial status of the study related to BRII-835 + BRII-179 in chronic hepatitis B and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BRII-835 + BRII-179 development?
- What are the key designations that have been granted to BRII-835 + BRII-179 for chronic hepatitis B?
- What is the forecasted market scenario of BRII-835 + BRII-179 for chronic hepatitis B?
- What are the forecasted sales of BRII-835 + BRII-179 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China?
- What are the other emerging products available and how are these giving competition to BRII-835 + BRII-179 for chronic hepatitis B?
- Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?
Key Topics Covered:
1. Report Introduction
2. BRII-835 + BRII-179 Overview in Chronic hepatitis B
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. BRII-835 + BRII-179 Market Assessment
5.1. Market Outlook of BRII-835 + BRII-179 in Chronic hepatitis B
5.2. 7MM and China Analysis
5.2.1. Market Size of BRII-835 + BRII-179 in the 7MM and China for Chronic hepatitis B
5.3. Country-wise Market Analysis
5.3.1. Market Size of BRII-835 + BRII-179 in the United States for Chronic hepatitis B
5.3.2. Market Size of BRII-835 + BRII-179 in Germany for Chronic hepatitis B
5.3.3. Market Size of BRII-835 + BRII-179 in France for Chronic hepatitis B
5.3.4. Market Size of BRII-835 + BRII-179 in Italy for Chronic hepatitis B
5.3.5. Market Size of BRII-835 + BRII-179 in Spain for Chronic hepatitis B
5.3.6. Market Size of BRII-835 + BRII-179 in the United Kingdom for Chronic hepatitis B
5.3.7. Market Size of BRII-835 + BRII-179 in Japan for Chronic hepatitis B
5.3.8. Market Size of BRII-835 + BRII-179 in China for Chronic hepatitis B
6. SWOT Analysis
7. Analysts' Views
8. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/52604y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
